Axioma Capital Partners

Axioma Capital Partners – works at the market of the venture funding since July, 2013, investing in projects at different stages and from the different industries.

For April, 2014 the investment strategy of the company is directed to creation of the businesses capable to pay off at the expense of dividends during the term of finding of the project in a portfolio. Axioma Capital Partners takes active part in project life up to introduction of the representative to operational management. Is a member of NABA and SKBA.

History

2014 Investments of $4 million into Medel

In April, 2014 the resident of Business incubator Ingria - the Medel company closed the investment transaction with Axioma Capital Partners investment company. According to the results of the agreement the startup will receive 4 million dollars of investments on commercialization of advanced development of "MEDEL". According to the results of negotiations with Axioma Capital Partners, the parties agreed about complete financing and closed the investment transaction.

Representative of Axioma Capital Partners investment company:

"We are interested in development of this and other developments of "MEDEL" as the method of treatment created by the project is extremely demanded and has high potential. Now from the budget of the Russian Federation about 10 billion rubles are annually selected for operations on endoprosthesis replacement of the joints destroyed by arthrosis – I believe that the state, insurance companies and patients will be interested in an opportunity to use the solution, effective from the medical and financial points of view".

Mikhail Morgunov, MEDEL project manager:

"The history of our development began in 1979 in Army medical college. We conducted pioneer researches of influence of electric field of electrets on processes of recovery of a bone tissue after injuries and diseases, including on recovery of functions of the joints affected with arthrosis. The created stimulators of an osteoreparation underwent broad clinical approbation and showed high efficiency. However due to the lack of financing further development of development was stopped".